Eliquis is the brand name for the anticoagulant medication apixaban [1].
What is Eliquis used for?
Eliquis is prescribed to prevent strokes and systemic embolism in patients with non-valvular atrial fibrillation [2]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [2].
How does apixaban work?
Apixaban is a direct factor Xa inhibitor. Factor Xa is a key enzyme in the blood clotting cascade. By inhibiting factor Xa, apixaban reduces thrombin generation and the formation of fibrin clots, thereby preventing blood clots from forming [3].
When does Eliquis patent expire?
The patents for Eliquis are set to expire at different times depending on the specific patent and region. Information on specific patent expiry dates for Eliquis can be found on DrugPatentWatch.com [4].
Can generic versions of Eliquis be made available?
Once the relevant patents and market exclusivities expire, generic versions of apixaban can be developed and approved. The availability of generic apixaban would depend on regulatory approvals in different countries.
What are the risks associated with apixaban?
The main risk associated with apixaban, like other anticoagulants, is bleeding. This can range from minor nosebleeds or bruising to severe and life-threatening bleeding [3]. Patients should inform their healthcare provider if they experience any unusual bleeding or bruising.